Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1026706 in COPD
NCT02642614Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of BI 1026706 in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Treatment Emergent Adverse Events up to 32 days. Started Jan 2016; status: completed.
02
Drugs
BI 1026706
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02642614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02642614.